SCHEMBL5032068

SCHEMBL5032068

Cc1cc(-c2ccccn2)sc1-c1ccc(C(N)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 2/20 0.50
MKNK1 Q9BUB5 3/20 0.46
MKNK2 Q9HBH9 3/20 0.46
IKBKB O14920 1/20 0.43
CDC7 O00311 1/20 0.43
ALOX5 P09917 1/20 0.42
KDM4E B2RXH2 3/20 0.42
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
CAMKK2 Q96RR4 1/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
GLA P06280 1/20 0.41
RAB9A P51151 1/20 0.41
MAP4K4 O95819 1/20 0.40
TGFBR1 P36897 2/20 0.40
CSNK1A1 P48729 2/20 0.40
CSNK1D P48730 2/20 0.40
CSNK1E P49674 2/20 0.40
MAPK14 Q16539 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5032069 0.83 KDM4E (0.46) IKBKBCDC7KDM4EESR1ESR2
SCHEMBL5029504 0.79 ESR1 (0.53) CHEK2MKNK1MKNK2CDC7ESR1
SCHEMBL8567489 0.79 IKBKB (0.51) IKBKBALOX5KDM4EMAPTNPC1
SCHEMBL5032076 0.77 MKNK1 (0.44) MKNK1MKNK2IKBKBCDC7KDM4E
SCHEMBL4927431 0.76 CHEK2 (0.67) CHEK2MKNK1MKNK2MAPTMAP4K4
SCHEMBL5033803 0.75 ESR1 (0.48) CHEK2MKNK1MKNK2ESR1ESR2
SCHEMBL5033802 0.75 AR (0.46) MKNK1MKNK2KDM4EESR1ESR2
SCHEMBL14360820 0.73 LMNA (0.55) KDM4EMAPTNPC1RAB9AALDH1A1
SCHEMBL5033854 0.72 MYC (0.46) CHEK2MKNK1MKNK2KDM4EESR1
SCHEMBL2170554 0.72 KDM4E (0.57) IKBKBALOX5KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1983831-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP claimed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US claimed
WO-2007087429-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO claimed
EP-1983831-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP disclosed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US disclosed
WO-2007087429-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses NLRP3, CCR1, NLRP1 CHEK2 4152/4885MKNK1 3158/4885MKNK2 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.